Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,150,380

« Back to Dashboard
Patent 6,150,380 protects PRILOSEC and is included in one NDA. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for PRILOSEC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,150,380

Title: Crystalline form of omeprazole
Abstract:The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole.
Inventor(s): Lovqvist; Karin (Molndal, SE), Sunden; Gunnel (Goteborg, SE), Noreland; David (Sodertalje, SE), Ymen; Ingvar (Saltsjo-Boo, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:09/202,251
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Use; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 8th percentile
Forward Citations: 8th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Pharms
CAPSULE, DELAYED REL PELLETS;ORAL019810-003Oct 5, 1995DISCNNo6,150,380*PED► subscribeY
Astrazeneca Pharms
CAPSULE, DELAYED REL PELLETS;ORAL019810-001Sep 14, 1989DISCNNo6,150,380*PED► subscribeY
Astrazeneca Pharms
CAPSULE, DELAYED REL PELLETS;ORAL019810-002Jan 15, 1998DISCNNo6,150,380*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,150,380

PCT Information
PCT FiledNovember 10, 1998PCT Application Number:PCT/SE98/02028
PCT Publication Date:February 25, 1999PCT Publication Number: WO99/08500

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.